Molecular studies revealed the presence of both p210 and p190 BCR-ABL chimeric transcripts. The B cellular clone was documented by IgH rearranged bands after digestion with all the three restriction enzymes used (data not shown).
In this study, immunophenotypic, FISH and molecular investigations revealed a B-CLL, characterized by CD5-CD19-positive mononuclear cells, IgH rearrangement and a del(13q), one of the most frequent changes in CLL. 7 In addition, the CML phenotype was characterized by t(9;22) and the presence of both p210 and p190 BCR-ABL chimeric transcripts. Moreover, FICTION studies clearly showed that BCR-ABL fusion and 13q loss independently occurred in the myeloid and lymphoid lineage, respectively. Several mechanisms explaining the association between the two chronic diseases may be suggested: excluding the leukemogenic effect of chemotherapy in our case, in which CML and CLL appeared simultaneously, the events might be coincidental. Nevertheless, the impaired immune surveillance accompanying CLL, might favor the appearance of a second neoplasia. On the other hand, it is to be remembered that in a small subset of B-CLL patients, the lymphoid genetic markers have been detected in CD34
+ bone marrow and peripheral blood cells, suggesting the involvement of early hematopoietic stem cells in the malignant transformation of B-CLL. 8 The clinical course of the disease in our patient showed, from the very beginning, a clear prevalence of the myeloid phenotype, until development of a myeloid blast crisis. As far as we know this is the first reported case in which a careful cytogenetic/immunophenotypic and molecular study has shown that simultaneous CML and CLL arise from distinct progenitors and evolving towards a frank myeloid acute leukemia. CDKN2/INK4A/p16 are common in many kinds of human malignancies. 2 Transforming growth factor ␤ (TGF-␤) may induce cell growth arrest through p27/Kip1 activation. TGF-␤ often loses its ability to arrest growth of transformed cells; this could potentially occur through a defect in p27/Kip1. Recent studies have shown that reduced or lack of p27 expression is associated with poor prognosis in breast, colorectal, prostate and lung cancers, as well as malignant lymphomas. 3 Moreover, point mutations of the p27/Kip1 gene were identified in both breast cancer and adult T cell leukemia/lymphoma (ATL) samples, and homozygous deletions of the p27/Kip1 gene were found in both nonHodgkin's lymphoma (NHL) and ATL samples. 4 These findings suggest that p27 is an important tumor suppressor. However, an inactivating mutation of the p27/Kip1 gene has not been identified in childhood acute lymphoblastic leukemia (ALL). In this report, we describe a biallelic inactivation of the p27/Kip1 gene identified in a case with childhood ALL.
Bone marrow samples obtained from a 3-year-old ALL (FAB L1) patient were used in this study. The patient was enrolled in the ongoing Multicenter Trial ALL-BFM 90 of childhood ALL of the German Berlin-Frankfurt-Mü nster (BFM) group. Complete remission (CR) was obtained after induction therapy. The corresponding normal DNA of the patient was obtained from the bone marrow after CR was achi-eved. Normal DNA samples were also obtained from the parents of the patient. Informed consent was obtained from the parents.
To look for point mutations by polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) analysis, the coding region of the p27/Kip1 gene was divided into three regions (Ia, Ib (both in exon 1), and II (exon 2)). 5 For region II, a shifted SSCP band, which was not observed in the normal control, was detected in the childhood ALL sample. The nucleotide sequence analysis revealed the nucleotide substitution of adenine for guanine (GAA → AAA) at codon 172, resulting in an amino acid substitution of lysine for glutamic acid (Glu → Lys) in this patient. We have performed an extensive mutational analysis of the p27/Kip1 gene using 611 samples from a variety of human malignancies, none had this mutation. [4] [5] [6] We also examined 100 DNAs from normal individuals and found no abnormalities. Moreover, this mutation has not been previously reported in the literature, to our knowledge, nor does it appear in the EST data bank. These findings tend to exclude the possibility that this nucleotide substitution is a rare polymorphism. A recent study showed that the carboxyl-terminal domain of p27 may activate CDC2 kinase activity during G 2 /M. 7 Therefore, this mutation could modify the normal controls for progression through the G 2 /M phase of the cell cycle. We were interested in p27 protein content in the leukemic cells, however, neither protein nor cells were available.
The nucleotide sequence analysis of normal DNA from the patient revealed both the mutant and normal sequences (Figure 1 ). These findings suggest that the mutation occurred in the germline. Sequence analysis of exon 2 amplified from the normal DNAs of both parents revealed both lysine and glutamic acid at codon 172 in the father of the proband. Only glutamic acid was identified at codon 172 in his mother ( Figure  1 ). These findings suggent that lysine at codon 172 in this patient was inherited from his father. The patient and the father are of normal height, and the father and his siblings are healthy. However, his father (grandfather of the proband) died from lung cancer and his wife (grandmother of the proband) died from kidney cancer. Moreover, the only sister of the grandmother died from a brain tumor. In contrast, the mother of our patient, her siblings, and parents are healthy with no history of cancer. A recent study has shown that mice having germline deletion of the p27/Kip1 gene are larger than the control animals and often develop pituitary tumors. However, our patient and his father are of normal height and body size. A longer follow-up period is required to relate the p27/Kip1 alteration to predilection to tumor formation.
We examined this ALL sample for LOH around the p27/Kip1 gene locus on chromosome 12 using seven highly informative microsatellite markers.
8 Figure 2 displays a representative autoradiograph showing LOH. The DNA from this individual showed LOH at the p27/Kip1 gene locus (D12S89) but maintained heterozygosity at the telomeric locus (D12S77). Moreover, the normal sequence was not observed in the autoradiogram using the leukemic cell sample. Taken together, the normal
Figure 1
Sequence analysis of the p27/Kip1 gene from the family members of the proband. Sequence analysis of exon 2 amplified from the normal DNAs of family members revealed codon 172 of both lysine (AAA) and glutamic acid (GAA) in the proband and father of the proband, while only codon 172 of glutamic acid (GAA) was identified in his mother.
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Figure 2
Representative autoradiograph showing loss of heterozygosity at p27/Kip1 locus in proband DNA. The patient shows loss of heterozygosity (LOH) at D12S89 with apparent retention of heterozygosity at D12S77. T, tumor DNA; N, normal DNA. p27/Kip1 allele was lost in the patient's leukemic cells. In accord with Knudson's hypothesis, a point mutation of one allele and loss of the remaining normal allele is necessary to impair completely the normal tumor-suppressing function of the p27/Kip1 gene. In our case, germline mutation of the p27/Kip1 gene occurred as the first event, and subsequent deletion of the normal allele inactivated normal p27 function completely.
Germline mutations of several tumor suppressor genes have been identified in some kinds of human leukemias. Li-Fraumeni syndrome is a consequence of a germline mutation of the p53 tumor suppressor gene. Affected individuals are predisposed to the development of multiple types of tumors, including leukemia and lymphoma. Ataxia-telangiectasia (A-T) is a multisystem recessive disease characterized by cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, sensitivity to radiomimetic agents, and increased risk of cancer. The ATM gene, responsible for A-T, was recently cloned at human chromosome band 11q22-23. Children with A-T frequently develop T-lineage ALL.
Human herpesvirus-6 as a possible cause of encephalitis and hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation Leukemia (2002) 16, 958-959. DOI: 10.1038/sj/leu/2402403 TO THE EDITOR Human herpesvirus 6 (HHV-6) is an increasingly recognized pathogen in hematopoietic stem cell transplantation (HSCT) recipients 1 and has recently been reported to cause encephalitis. To date, 13 cases of HHV-6 encephalitis after HSCT have been reported.
2-4 HHV-6 has been found to have greater susceptibility to ganciclovir and foscarnet. Foscarnet, however, is preferred because of a higher concentration in the cerebrospinal fluid (CSF) and only two cases of encephalitis were treated with just ganciclovir in previous reports. 2 We experienced two cases of HHV-6 encephalitis after allogeneic HSCT and their characteristics are summarized in Table 1 . One patient (case 1) began to show agitation on day +21, with signal abnormalities in radiologic study (Figure 1a) , and a cellular hematuria developed over the following days. The other patient (case 2), 1 month after transplant, presented with fever, generalized skin rash and disorientation. His mental status finally decreased to a drowsy state on day +51. The possibilities of drug toxicity and metabolic influences were ruled out in both cases. Treatment with i.v. ganciclovir (5 mg/kg every 12 h) commenced when the PCR for HHV-6 variant B from the CSF, which was tested elsewhere, 5 was positive (Figure 1b) . The DNA of HHV-6 variant A, HSV type 1 and 2, EBV, and CMV was not detected from the CSF. The patients' neurological symptoms were resolved with 3 weeks of ganciclovir therapy, and clinical improvements accompanied with a regression of the signal abnormalities on MRI (case 1) and conversion of PCR to negative result in the CSF and serum samples.
Further analyses were performed to reveal the cause of hematuria in case 1. PCR analysis for the HHV-6 variant B from the urine samples showed positive results. No bacterial, fungal or mycobacterial pathogens were detected in the urine samples. DNA PCR 6 for BKV and JCV and immunofluorescence staining with anti-adenovirus antibody (mouse monoclonal antibody, Chemicon International, Temecula, CA, USA) from the urine was also negative. Interestingly, an improvement in CNS symptoms also accompanied with a gradual decrease and final disappearance of the hematuria and PCR negativity for HHV-6 in the urine samples.
As HHV-6 has been found in the renal tubular endothelial cells and kidney, 7 these clinical data imply a role of HHV-6 in hematuria that develops after HSCT. This suggests that HHV-6 is associated with urinary tract damage, but it cannot be considered as conclusive evidence because sporadic PCR positivity for HHV-6 in the urine was found in 9% of patients after HSCT. 8 In conclusion, these cases stress the emerging role of HHV-6 in encephalitis after HSCT and usefulness of ganciclovir therapy. A link between a HHV-6 infection and a hemorrhagic cystitis has never been described elsewhere and still remains uncertain. Further research should be undertaken. 
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